Exploration of Targeted Anti-tumor Therapy · 2024 · 10 citations · 85 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyInnate ImmunityCytokine BiologyInnate Immune ResponseInnate Lymphoid CellsInterferon ResponsesT Cell BiologyT Cell Responses To TumorsGroup 1 Innate Lymphoid CellsInnate Immune Cell FunctionInnate Immune CytokinesInnate Immune EffectorsInnate Lymphoid Cell BiologyInnate Lymphoid Cell CytokinesInnate Lymphoid Cell ResponsesInterferon-gamma Responses
Innate lymphoid cells (ILCs) are the most recently discovered class of innate immune cells found to have prominent roles in various human immune-related pathologies such as infection and autoimmune diseases. However, their role in cancer was largely unclear until recently, where several emerging studies over the past few years unanimously demonstrate ILCs to be critical players in tumour immunity. Being the innate counterpart of T cells, ILCs are potent cytokine producers through which they orchestrate the overall immune response upstream of adaptive immunity thereby modulating T cell function. Out of the major ILC subsets, ILC1s have gained significant traction as potential immunotherapeutic candidates due to their central involvement with the anti-tumour type 1 immune response. ILC1s are potent producers of the well-established anti-tumour cytokine interferon γ (IFNγ), and exert direct cytotoxicity against cancer cells in response to the cytokine interleukin-15 (IL-15). However, in advanced diseases, ILC1s are found to demonstrate an exhausted phenotype in the tumour microenvironment (TME) with impaired effector functions, characterised by decreased responsiveness to cytokines and reduced IFNγ production. Tumour cells produce immunomodulatory cytokines such as transforming growth factor β (TGFβ) and IL-23, and through these suppress ILC1 anti-tumour actfivities and converts ILC1s to pro-tumoural ILC3s respectively, resulting in disease progression. This review provides a comprehensive overview of ILC1s in tumour immunity, and discusses the exciting prospects of harnessing ILC1s for cancer immunotherapy, either alone or in combination with cytokine-based treatment. The exciting prospects of targeting the upstream innate immune system through ILC1s may surmount the limitations associated with adaptive immune T cell-based strategies used in the clinic currently, and overcome cancer immunotherapeutic resistance.
85
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text
Medicine, Immunology, Oncology +17
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Seth B. Coffelt, Kelly Kersten, Chris W. Doornebal et al. · Nature · 2015 · 1.7K citations · Full text
Medicine, Immunology, Oncology +14
IL-15 Receptor Maintains Lymphoid Homeostasis by Supporting Lymphocyte Homing and Proliferation
James P. Lodolce, David L. Boone, Sophia Chai et al. · Immunity · 1998 · 1.3K citations · Full text